文献速递临床试验与 GCP

二甲双胍改善下肢外周动脉疾病患者步行能力:PERMET随机临床试验

Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

这项在美国4个中心进行的随机双盲临床试验,纳入202例50岁及以上、不合并糖尿病的下肢外周动脉疾病患者,随机接受二甲双胍(n=97)或安慰剂(n=105)治疗6个月。结果显示,二甲双胍组与安慰剂组的6分钟步行距离变化无显著差异(组间校正差值1.1米,95%CI -16.3至18.6米,P=0.90),所有次要结局亦无显著改善。

要点

  • 二甲双胍未显著改善下肢外周动脉疾病患者的6分钟步行距离。
  • 二甲双胍组与安慰剂组的6分钟步行距离组间校正差值为1.1米(95%CI -16.3至18.6米,P=0.90)。
  • 二甲双胍未显著改善任何次要结局。

核心结论

  • 在不合并糖尿病的下肢外周动脉疾病患者中,与安慰剂相比,二甲双胍未改善6个月随访时的6分钟步行距离。
  • 这些结果不支持使用二甲双胍改善外周动脉疾病患者的步行能力。

研究设计与样本

  • 随机双盲临床试验,在美国4个中心进行。
  • 入组始于2017年5月23日,止于2025年2月17日,目标212例中实际入组202例(95%),因资金限制提前终止入组。
  • 纳入50岁及以上、患下肢外周动脉疾病的成人,随机接受二甲双胍(n=97)或安慰剂(n=105)治疗6个月。
  • 最终随访于2025年8月19日完成。
  • 主要结局为6个月时6分钟步行距离的变化(最小临床重要差异为8至20米)。

主要发现

  • 202例随机化患者平均(标准差)年龄69.6(8.4)岁,女性56例(28%),黑人79例(39%);179例(89%)完成6个月随访。
  • 二甲双胍组6分钟步行距离从358.6米降至353.2米,组内变化-5.4米;安慰剂组从359.8米降至354.5米,组内变化-5.3米;组间校正差值为1.1米(95%CI -16.3至18.6米;P=0.90)。
  • 与安慰剂相比,二甲双胍未显著改善任何次要结局。
  • 最常见的严重不良事件为心血管事件(二甲双胍组3.1%,安慰剂组1.9%)。
  • 最常见的非严重不良事件为消化不良/胃部不适(二甲双胍组64.9%,安慰剂组40.6%)和头痛(二甲双胍组37.2%,安慰剂组49.5%)。

临床怎么用

  • 原文结论指出,这些结果不支持使用二甲双胍改善外周动脉疾病患者的步行能力。

局限性

  • 原文报告因资金限制,目标212例中实际入组202例(95%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lower extremity peripheral artery disease (PAD) is a disabling cardiovascular condition that impairs walking ability. Few effective therapies improve walking performance in people with PAD. Metformin is a widely available and inexpensive therapy for type 2 diabetes with pleiotropic effects that include activating AMP-activated protein kinase, reducing oxidative stress, and stimulating endothelial nitric oxide synthase (eNOS). OBJECTIVE: To determine whether metformin improves 6-minute walk distance, compared with placebo, in people with PAD and without diabetes at 6-month follow-up. DESIGN, SETTING, AND PARTICIPANTS: Randomized double-blind clinical trial involving 4 centers in the US. Enrollment began May 23, 2017, and ended on February 17, 2025, with 202 of the targeted 212 (95%) enrolled, due to funding limitations. Participants were adults aged 50 years and older with PAD. Final follow-up occurred August 19, 2025. INTERVENTIONS: Participants with PAD were randomized to receive either metformin (n = 97) or placebo (n = 105) for 6 months. MAIN OUTCOMES AND MEASURES: The primary outcome was 6-month change in 6-minute walk distance (minimum clinically important difference, 8 to 20 m). Secondary outcomes were maximal treadmill walking time, pain-free treadmill walking time, the Walking Impairment Questionnaire distance and speed scores, the Short-Form 36 physical functioning score, and brachial artery flow-mediated dilation. Results were adjusted for site and the baseline value for each outcome measure. RESULTS: Of 202 randomized patients (mean [SD] age, 69.6 [8.4] years, 56 [28%] female, 79 [39%] Black), 179 (89%) completed 6-month follow-up. Metformin did not significantly improve 6-minute walk distance compared with placebo (metformin: 358.6 to 353.2 m, within-group change: -5.4 m; placebo: 359.8 to 354.5 m, within-group change: -5.3 m, adjusted between-group difference: 1.1 m [95% CI, -16.3 to 18.6 m]; P = .90). Compared with placebo, metformin did not significantly improve any secondary outcomes. The most common serious adverse events were cardiovascular events (3.1% for metformin and 1.9% for placebo). The most common nonserious adverse events were indigestion/stomach upset (64.9% for metformin and 40.6% for placebo) and headache (37.2% for metformin and 49.5% for placebo). CONCLUSIONS AND RELEVANCE: Among people with PAD without diabetes, metformin did not improve 6-minute walk distance at 6-month follow-up compared with placebo. These results do not support metformin for improving walking performance in patients with PAD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03054519.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. McDermott MM, Domanchuk KJ, Tian L, et al. Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial. JAMA. 2026. PMID: 41205146. doi:10.1001/jama.2025.21358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。